Northway Biotech
16.5.2023 14:32:41 CEST | ACCESS Newswire | Press release
KIEL, GERMANY / ACCESSWIRE / May 16, 2023 / tiakis Biotech AG (tiakis), in collaboration with its CDMO partner Northway Biotech, is pleased to announce the successful completion of a technology transfer and ramp-up of manufacturing capabilities for Tiprelestat, a pioneering anti-inflammatory and tissue-protective drug being developed for the prevention of postoperative inflammatory complications following major surgery, treatment of COVID-19 and pulmonary arterial hypertension. For the first time worldwide, a clinical trial is being supported by Tiprelestat study material produced at an industrial fermentation scale, representing a ten-fold increase in manufacturing potential to 3,000 L.
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.tiakis Biotech AG and Northway Biotech: Successful Tech Transfer and Expansion of Manufacturing Capabilities for Tiprelestat
"The marked increase in manufacturing capabilities lays the foundation for the next stage of tiakis' development programs, with the recent start of our COMCOVID phase Ib/II clinical trial being a prime example," said Martin Voss, tiakis Biotech AG co-CEO.
The enhanced production capabilities is a result of the successful completion of a technology transfer and subsequent ramp-up program, achieved in a short time through close collaboration with end-to-end biologics CDMO Northway Biotech, based in Vilnius, Lithuania.
Reflecting on this milestone, Vladas Algirdas Bumelis, CEO of Northway Biotech, stated: "The confidence our partners have placed in our two-decade-long expertise has enabled us to collaboratively scale up the process and meet tiakis' deadlines. Our state-of-the-art 3,000 L stainless-steel fermenter train was utilized to carry out the implementation successfully. We extend our sincere well-wishes to our partners as they move forward with their innovative drug through clinical trials, and we look forward to future collaborations."
André Markmann, VP Business Development of Northway Biotech, added: "This partnership exemplifies our commitment to assist our partners in achieving their objectives by leveraging our technical expertise and operational capabilities. We are immensely proud to be part of this groundbreaking project, which addresses a significant unmet medical need."
By attaining this pharmaceutical and technological milestone, tiakis and Northway Biotech have demonstrated their capabilities to pave the way towards groundbreaking achievements as pioneers in their respective fields. The success of this fast-paced project is characterized by strong collaborative interaction, mutual trust, and flexibility between the two companies.
About Tiprelestat
tiakis biopharmaceutical drug candidate Tiprelestat promises an excellent therapeutic benefit-risk profile for use as an anti-inflammatory and tissue-protective drug. Tiprelestat is identical to the human protein elafin with high specificity for tissue-destroying and inflammation-promoting proteases. The development program of Tiprelestat is focused on the late-stage development of Tiprelestat in major surgery and early-stage development in pulmonary arterial hypertension (PAH) and COVID-19.
About tiakis Biotech AG
tiakis focuses on the discovery and development of therapeutic solutions based on its innovative biopharmaceutical Tiprelestat for life-threatening surgeries and life-threatening diseases such as PAH and COVID-19. tiakis seeks partners and investors for the development, commercial-scale manufacturing, marketing and distribution of the product. The company tiakis Biotech AG is located in Kiel, Germany (www.tiakis.bio).
About Northway Biotech
Northway Biotech is a leading contract development and manufacturing organization (CDMO) supporting customers worldwide. Its highly experienced, professional team executes projects at any stage, from cell line construction and process development to cGMP manufacturing of biopharmaceutical products. The company's wide-ranging expertise and vertically integrated service offering translate to the ability to rapidly execute multiple projects from its state-of-the-art GMP facilities while ensuring full process and product compliance at all stages of research, development and commercial manufacturing. Northway Biotech is a privately owned company founded in 2004 and located in Vilnius, Lithuania, London, United Kingdom, and in Waltham, MA, US. Further information can be found on Northway's website www.northwaybiotech.com.
Contact Information
Vladas Bumelis
CEO and Chairman of the Board
vladas.bumelis@northwaybiotech.com
SOURCE: Northway Biotech
To view this piece of content from stats.newswire.com, please give your consent at the top of this page.View source version on accesswire.com:
https://www.accesswire.com/755218/tiakis-Biotech-AG-and-Northway-Biotech-Successful-Tech-Transfer-and-Expansion-of-Manufacturing-Capabilities-for-Tiprelestat
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.
About ACCESS Newswire
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
AccessPay Partners With PayPoint to Strengthen Fraud and Error Prevention for Corporate Payments3.3.2026 10:00:00 CET | Press release
MANCHESTER, UK / ACCESS Newswire / March 3, 2026 / AccessPay, the leading bank integration provider, today announced a new partnership with PayPoint to integrate PayPoint's Confirmation of Payee (CoP) capability into AccessPay's payments automation suite for modern finance teams. With £258m lost to authorised push payment (APP) fraud in the first half of 2025 alone, organisations need access to robust payment controls that scale with their operations.1 PayPoint's CoP offering enables AccessPay's customers to verify payee account details as part of their payment workflows, reinforcing AccessPay's position at the centre of a growing ecosystem of technologies designed to automate and de-risk the Office of the CFO. CoP, also known as Account Name Verification (ANV), is a valuable anti-fraud measure that checks the accuracy of payee details before funds are sent. It can be used to confirm payee details at the point of collection, when creating a payment instruction, or both. PayPoint's CoP
Affiliate of Pacific Avenue Capital Partners to Acquire Care.com from IAC3.3.2026 01:00:00 CET | Press release
LOS ANGELES, CA / ACCESS Newswire / March 2, 2026 / Pacific Avenue Capital Partners ("Pacific Avenue"), a Los Angeles-headquartered private equity firm focused on corporate carve-outs and other complex transactions in the middle market, today announced that an affiliate of Pacific Avenue has entered into an agreement to acquire Care.com from IAC Inc. (NASDAQ:IAC). Care.com is a leading platform and brand in the growing $400 billion market for family care, anchored by the largest online network of background-checked child and senior caregivers in the U.S. Care.com operates both a scaled consumer marketplace and an enterprise benefits platform. Since 2007, more than 45 million people have turned to Care.com to find child care, senior care, pet care and housekeeping support. Care.com also partners with more than 700 employers, including many of the Fortune 100, to deliver care-related benefits that combine access to the Care.com platform and comprehensive backup care solutions provided in
Stagwell Launches Stagwell Search+: The Industry's First Agentic Platform To Win AI Search2.3.2026 14:30:00 CET | Press release
New media solution enables brands to win discoverability, visibility, positive sentiment, and outcomes across major AI systems NEW YORK, NY AND LONDON, UK / ACCESS Newswire / March 2, 2026 / Stagwell (NASDAQ:STGW), the global challenger network transforming marketing through AI, today announced the global launch of Stagwell Search+, the industry's first agentic platform for AI Search experiences. Built by Assembly, Stagwell's global omnichannel media agency, in partnership with Emberos, the operating system for AI visibility, Stagwell Search+ is a category-defining solution to master the transition from traditional search engines to AI search experiences. As Large Language Models (LLMs) increasingly mediate how people discover, compare, and choose, Stagwell Search+ helps brands optimize not just for clicks and traffic, but for a new era of search where AI guides decisions and the goal is to be chosen. The solution combines an agentic platform with a differentiated framework that improv
Polaris Renewable Energy Announces Approval of SO1 Agreement by PREPA2.3.2026 13:50:00 CET | Press release
TORONTO, ON / ACCESS Newswire / March 2, 2026 / Polaris Renewable Energy Inc. (TSX:PIF) ("Polaris" or the "Company"), is pleased to announce that, at a meeting held on February 19, 2026, the Governing Board of the Puerto Rico Electric Power Authority ("PREPA") approved the Battery Energy Storage System Standard Offer Agreement ("SO1 Agreement"). The Company received formal written notice of approval on February 27, 2026. The execution of the SO1 Agreement between PREPA and Polaris Power US, Inc. ("PPUS"), a wholly owned subsidiary of Polaris, remains subject to the approval of the Financial Oversight & Management Board (FOMB) of Puerto Rico, which constitutes the next required step in the process. The Company remains optimistic that the FOMB review and authorization will progress in a timely manner relative to prior regulatory milestones achieved for this project. The SO1 Agreement forms part of the Puerto Rico Accelerated Storage Addition Program ("ASAP"), a strategic initiative aimed
MEWA Launches the First Saudi Water Week Next April to Shape the Future of the Water Sector Regionally and Globally28.2.2026 12:55:00 CET | Press release
MEWA Launches the First Saudi Water Week Next April RIYADH, SA / ACCESS Newswire / February 28, 2026 / The Ministry of Environment, Water and Agriculture will inaugurate the first Saudi Water Week during the second week of April. This premier national and international forum will convene policymakers, specialists, researchers, private sector entities, and relevant water sector organizations from both within Saudi Arabia and internationally. This initiative underscores the Ministry's sustained commitment to bolstering water security, reinforcing the sustainable governance of water resources, and fostering scientific research and innovation within this critical sector. The Ministry clarified that the Saudi Water Week will feature several specialized events, including the Arab Water Forum and the Second Stakeholders Meeting for the World Water Forum 2027, in addition to detailed presentations of the achievements of the water sector in the Kingdom and other national sectors. The organizati
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom